⌘K
Loading ticker…
As of 2026-08-21, Regeneron Pharmaceuticals Inc (REGN) has a 3-month relative strength percentile of 87 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 57. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.8%, relative volume 0.97×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
REGN is held by 97 ETFs as of May 2026. Top owner: QQQM at 0.28% weight, $271M notional. Top 3 carry $595M.
Held by 347 ETFs · $14.8B across latest filings · largest weight 8.55% (TBXU).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| QQQMInvesco NASDAQ 100 ETF | 0.28% | $271M | −0.15 pp |
| VHTVanguard Health Care ETF | 1.00% | $191M | −0.20 pp |
| SCHGSchwab U.S. Large-Cap Growth ETF | 0.22% | $132M | −0.08 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.09% | $66M | −0.04 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.57% |
| $65M |
| −0.24 pp |
| VONVVanguard Russell 1000 Value ETF | 0.19% | $40M | −0.06 pp |
| MGV | 0.31% | $39M | −0.08 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.08% | $37M | −0.03 pp |
| TQQQProShares UltraPro QQQ | 0.09% | $34M | −0.17 pp |
| FNDXSchwab Fundamental U.S. Large Company Index ETF | 0.13% | $33M | −0.05 pp |
Showing 10 of 97 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | REGN Jan avg: 0.75% median: 0.59% win: 50% σ: 6.43% n: 4 2022-04-12 → 2026-07-31 | REGN Feb avg: 3.00% median: 3.15% win: 100% σ: 2.19% n: 4 2022-04-12 → 2026-07-31 | REGN Mar avg: -0.68% median: -0.76% win: 25% σ: 7.07% n: 4 2022-04-12 → 2026-07-31 | REGN Apr avg: -6.54% median: -7.46% win: 0% σ: 2.62% n: 5 2022-04-12 → 2026-07-31 | REGN May avg: -5.71% median: -8.26% win: 40% σ: 11.24% n: 5 2022-04-12 → 2026-07-31 | REGN Jun avg: 0.47% median: 1.43% win: 60% σ: 7.61% n: 5 2022-04-12 → 2026-07-31 | REGN Jul avg: 6.11% median: 3.25% win: 80% σ: 9.31% n: 5 2022-04-12 → 2026-07-31 | REGN Aug avg: 6.88% median: 8.12% win: 75% σ: 5.09% n: 4 2022-04-12 → 2026-07-31 (current) | REGN Sep avg: 0.92% median: -1.80% win: 25% σ: 12.62% n: 4 2022-04-12 → 2026-07-31 | REGN Oct avg: -0.22% median: 1.73% win: 50% σ: 15.99% n: 4 2022-04-12 → 2026-07-31 | REGN Nov avg: 3.81% median: 3.01% win: 75% σ: 12.54% n: 4 2022-04-12 → 2026-07-31 | REGN Dec avg: -0.88% median: -2.54% win: 25% σ: 5.27% n: 4 2022-04-12 → 2026-07-31 |